Introduction
Hypertrophic cardiomyopathy (HCM) is a genetic cardiac condition characterized by abnormal thickening of the heart muscle, which can impede blood flow and predispose patients to serious complications. Among the most concerning risks are acute cerebrovascular events, including ischaemic stroke, transient ischaemic attack (TIA), and systemic thromboembolism. While HCM itself increases these risks, the presence of atrial fibrillation (AF)—a common irregular heart rhythm—is known to worsen the prognosis. This systematic review and meta-analysis seeks to quantify the incidence of these events and evaluate the specific impact of AF on the HCM patient population.
Methodology
Researchers conducted a comprehensive meta-analysis by synthesizing data from 35 previously published articles, encompassing a total of 42,570 patients. The study queried major medical databases (PubMed, Scopus, Embase, and Cochrane) for literature published up to March 2021.
The primary objective was to compare the incidence of ischaemic strokes, TIAs, and systemic thromboembolism in HCM patients with AF versus those without. Statistical analysis was performed using StataSE 16, calculating pooled incidence and Risk Ratios (RR). Heterogeneity across the studies was assessed using the $I^2$ test to determine the consistency of the findings.
Key Findings
The AF "Risk Multiplier"
The most significant finding of the study is that AF acts as a primary driver of neurological events in HCM patients. The analysis revealed that HCM patients with concomitant AF are 3.26 times more likely to experience a stroke or TIA compared to those without the arrhythmia (RR 3.26, 95% CI 1.75–6.08, p<0.001).
Overall Incidence Rates
Across the 24 studies that specifically provided stroke/TIA data (n=37,643), the pooled incidence of these events was 7.45% (95% CI: 5.80–9.52%). This baseline risk underscores the inherent vulnerability of the HCM population to thromboembolic complications.
Apical HCM Subgroup
The study also addressed the risk profile of apical HCM—a variant where thickening occurs at the tip of the heart. Contrary to some clinical perceptions that this subtype might be lower risk, the study found an incidence rate of 9.30% (95% CI 6.64–12.87%). This suggests that patients with apical HCM carry a similar, if not slightly higher, burden of acute cerebrovascular events as the broader HCM population.
Discussion and Clinical Implications
The high statistical significance of the findings regarding AF provides strong evidence for aggressive stroke prevention strategies. Early detection of AF and the timely initiation of anticoagulation therapy are essential for mitigating the tripled risk of stroke in these patients.
Furthermore, the data regarding apical HCM indicates that morphological variants should not lead to a lower clinical suspicion of thromboembolic risk. All HCM patients, regardless of subtype, require careful monitoring for arrhythmias and associated ischaemic risks.
Limitations
The study noted high heterogeneity ($I^2 = 76.0$), indicating significant variation in how different studies reported their findings. This variation may stem from differences in study design, patient demographics, or the definitions used for thromboembolic events. Additionally, some studies did not specify the exact type of thromboembolic event, which may mask nuances between different types of clots. Future research should aim for more standardized reporting to further refine these risk models.
Summary updated